COMMUNIQUÉS West-GlobeNewswire

Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering
06/03/2026
Short Term Tranche Warrants Potentially Raise $10.4 Million within 12 months of Closing SAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a [...]
Solid Biosciences Announces Oversubscribed $240 Million Private Placement
06/03/2026
CHARLESTOWN, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that [...]
New England Journal of Medicine publishes phase III ALLEGORY data showing Roche’s Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus
06/03/2026
Over three quarters of people on Gazyva/Gazyvaro plus standard therapy achieved at least a four-point improvement in SRI-4, a measure that assesses disease severity and symptoms Gazyva/Gazyvaro has the potential to [...]
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
06/03/2026
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 6 March 2026 at 16.00 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]
Claritas iPET™ Approved by Australia TGA to Supply the Medical Software Device for Image Processing Enabling Diagnostic Quality Images from Short Scan Time and/or Low Dose PET, PET-CT/MRI Scans
06/03/2026
LONDON and SYDNEY, March 06, 2026 (GLOBE NEWSWIRE) -- Claritas NucMed Technologies Ltd (Claritas), a healthcare technology company specializing in state-of-the-art image enhancement, noise reduction, segmentation and [...]
Intended Retirement of Independent Non-executive Director and changes of composition of board committees
06/03/2026
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Professor Mok Shu Kam, Tony has [...]
argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
06/03/2026
Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as the first targeted treatment for patients living with ocular MG Additional data from ADAPT SERON – the largest study of patients with gMG who [...]
Fagron publishes its Annual Report 2025
06/03/2026
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 6 March 2026 7AM CET Fagron publishes its Annual Report 2025 Fagron, the leading global player in pharmaceutical compounding, today publishes its [...]
Rakovina Announces Closing of $1 Million Debenture Unit Private Placement and Debt Settlement Agreements
06/03/2026
VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV; FSE: 7JO0) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through [...]
Quipt Home Medical Receives Final Order Approving Arrangement
06/03/2026
CINCINNATI, March 05, 2026 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “ Company ”) (NASDAQ: QIPT; TSX: QIPT)‎, a U.S. based home medical equipment provider, focused on end-to-end respiratory care, announces that [...]
Paingone Plus TENS Pen Featured in 2026 Consumer Report Examining FDA Clearance Status, TENS Pain Therapy Research, and Portable Pain Relief Device Verification
06/03/2026
A 2026 consumer research report examining Paingone Plus TENS pen searches, portable TENS pain relief device claims, FDA clearance status, published nerve stimulation therapy research, doctor endorsement context, and [...]
Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results
05/03/2026
Completed pre-IND meeting following MGX-001 preclinical data demonstrating curative FVIII activity in non-human primates (NHPs) and remains on track for global regulatory submission including investigational new drug [...]
Calidi Biotherapeutics Announces Proposed Public Offering
05/03/2026
SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today [...]
President & CEO Letter to Shareholders
05/03/2026
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, March 05, 2026 (GLOBE NEWSWIRE) -- Dear Nova Leap Health Corp. (“Nova Leap” or the “Company”) Shareholders: [...]
Nova Leap Health Corp. Posts Fourth Quarter and Record Full-Year 2025 Revenues and Adjusted EBITDA
05/03/2026
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, March 05, 2026 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a [...]
COSCIENS Provides Strategic Update
05/03/2026
TORONTO, ONTARIO, March 05, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) (“ COSCIENS ” or the “ Company ”) today announced that the Company has made a strategic decision to cease funding [...]
MannKind Announces Settlement of Convertible Senior Notes
05/03/2026
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced the settlement of the remaining $36.3 million aggregate principal amount of 2.50% [...]
MediWound Files Annual Report on Form 20-F
05/03/2026
MediWound Files Annual Report on Form 20-F YAVNE, Israel, March 5 , 202 6 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, t oday announced that it has filed [...]
Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026
05/03/2026
Late-breaking oral presentation to feature primary analysis from KYSA-8 registrational trial in stiff person syndrome (SPS) Oral presentation on updated KYSA-6 Phase 2 data in generalized myasthenia gravis (gMG) [...]

Pages